A Study of Eribulin Mesylate With Trastuzumab for Advanced or Recurrent Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Breast Cancer
Clinical trial NCT01432886 · COMPLETED
Trial details
- NCT number
- NCT01432886
- Sponsor
- Eisai Co., Ltd.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2011-10-01
- Primary completion
- 2013-08-01
- Enrollment
- 12
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.